Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending July 04, 2006. The report serves as a notification of transactions involving Directors, Persons Discharging Managerial Responsibility, or Connected Persons in the company's Ordinary Shares, filed pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This document is strictly a regulatory notification regarding share transactions and does not contain financial performance data.
Material Changes
The filing details specific share transfers from the GlaxoSmithKline Employee Trust ("the GSK Trust") to participants in the SmithKline Beecham Employee Share Option Plan 1991:
- June 30, 2006: Transfer of 68,711 Ordinary Shares.
- July 3, 2006: Transfer of 76,335 Ordinary Shares.
These transactions were advised to the Company on July 3 and July 4, 2006, respectively.
Guidance, Outlook, and Risks
The filing contains no management commentary, financial guidance, outlook, or discussion of risks and contingencies. It notes that the GSK Trust is a discretionary trust for current and former employees, and that three directors (Dr J-P Garnier, Dr M M Slaoui, and Mr J S Heslop) are interested in the shares held in the trust in the same capacity as other employees.
Key Facts for Investor Verification
- Verify the total number of shares transferred to the SmithKline Beecham Employee Share Option Plan 1991 during the reporting period (145,046 shares).
- Confirm the identity of the trustee, Abacus (GSK) Trustees Limited, and its role in the GSK Trust.
- Note that the filing is a compliance notification under Disclosure Rule 3.1.4R(1)(b) and does not reflect operational or financial results.